產(chǎn)品列表

我們提供RUO和GMP兩種級(jí)別的Anti-CD抗體，助力您從發(fā)現(xiàn)到臨床階段的研究。

• RUO級(jí)Anti-CD抗體

  產(chǎn)品編號(hào)	名稱	數(shù)量	價(jià)格	操作
  A02199	Anti-Human CD3 Antibody (OKT3), mAb, Mouse		￥400.00 100 μg
  A02211	Anti-Human CD4 Antibody (F001), mAb, Mouse		￥400.00 100 μg
  A02212	Anti-Human CD8 Antibody (F002), mAb, Mouse		￥400.00 100 μg
  A02213	Anti-Human CD28 Antibody (F105), mAb, Mouse		￥400.00 100 μg

• GMP級(jí)Anti-CD抗體

  產(chǎn)品編號(hào)	名稱	數(shù)量	價(jià)格	操作
  GMPA02199	GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse		- 100 μg 1 mg
  GMPA02213	GMP Anti-Human CD28 Antibody (F105), mAb, Mouse		- 100 μg 1 mg

• 新品預(yù)告

  產(chǎn)品編號(hào)	名稱	訂購(gòu)
  GMPA02211	GMP Anti-Human CD4 Antibody (F001), mAb, Mouse	咨詢
  GMPA02212	GMP Anti-Human CD8 Antibody (F002), mAb, Mouse	咨詢

*沒(méi)找到您需要的GMP級(jí)Anti-CD抗體？ 聯(lián)系我們并提供RUO級(jí)產(chǎn)品貨號(hào)或CD分子名稱。金斯瑞的GMP蛋白平臺(tái)可將RUO級(jí)目錄產(chǎn)品快速轉(zhuǎn)化為GMP級(jí)。

*金斯瑞可根據(jù)您的要求提供抗體標(biāo)記。包括 PE、FITC、iFluor 488、iFuor 555、iFuor 647 和Biotin。如需標(biāo)記Anti-CD抗體，請(qǐng)聯(lián)系我們。

RUO 對(duì)比 GMP

• 質(zhì)控放行標(biāo)準(zhǔn)

  項(xiàng)目	GMP*級(jí)抗體	RUO級(jí)抗體
  濃度	5.0 ± 0.5 mg/mL	1.0 ± 0.1 mg/mL
  外觀	澄清、無(wú)色液體	澄清、無(wú)色液體
  純度	SEC-HPLC：≥ 95%	SEC-HPLC：≥ 95%
  內(nèi)毒水平	< 0.1 EU/mg	< 0.5 EU/μg
  活性	經(jīng)驗(yàn)證	經(jīng)驗(yàn)證
  鑒定	經(jīng)質(zhì)譜方法驗(yàn)證，序列與理論序列完全一致	/
  HCP殘留	≤ 100.0 ng/mg	/
  HCD殘留	≤ 10.0 pg/mg	/
  Protein A殘留	≤ 10.0 ng/mg	/
  無(wú)菌	無(wú)菌	/

  *GMP 級(jí)是金斯瑞用來(lái)描述在符合GMP規(guī)范的環(huán)境中生產(chǎn)的CD抗體的一個(gè)特定術(shù)語(yǔ)。該抗體生產(chǎn)遵循GMP的指導(dǎo)原則，具有嚴(yán)格的過(guò)程控制和完整的文件記錄。金斯瑞可提供文件記錄，現(xiàn)場(chǎng)審計(jì)，及其它可幫助您的項(xiàng)目在特定區(qū)域進(jìn)行申報(bào)的支持。詳細(xì)了解我們的 GMP的能力。

• GMP級(jí)Anti-CD抗體特色

  體外細(xì)胞培養(yǎng)可用性	GMP生產(chǎn)合規(guī)性	高穩(wěn)定性和批間一致性
  無(wú)菌無(wú)動(dòng)物源	可追溯文件記錄	長(zhǎng)期穩(wěn)定性研究
  超低內(nèi)毒水平（< 0.1 EU/mg）	符合GMP生產(chǎn)規(guī)范	加速穩(wěn)定行研究
  HCD, HCP, Protein A殘留控制	嚴(yán)格的質(zhì)量控制和放行檢測(cè)	凍融穩(wěn)定性研究
  高純度及高親和力	可提供審計(jì)及法規(guī)相關(guān)支持	批次間質(zhì)量一致

應(yīng)用案例

• 抗人CD3和CD28抗體激活T細(xì)胞

  抗CD3和抗CD28抗體與 T 細(xì)胞表面表達(dá)的相應(yīng)CD標(biāo)志物結(jié)合，分別為T(mén)細(xì)胞激活提供第一和第二信號(hào)。共刺激的激活信號(hào)誘導(dǎo)T細(xì)胞快速增殖，在適應(yīng)性免疫反應(yīng)和免疫治療中起著至關(guān)重要的作用。

  • 抗人CD3和CD28抗體激活T細(xì)胞快速增殖
    

    Figure 1. GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. GMPA02199) was used for primary T cell activation together with anti-Human CD28 antibody. The percentage of activated T cells were measured by flow cytometry. Data showed that GenScript GMP Anti-Human CD3 Antibody (OKT3), mAb, Mouse outperformed the competing products in activating primary T cells.

  • 抗人CD3和CD28抗體刺激報(bào)告細(xì)胞系信號(hào)響應(yīng)
    

    Figure 2. CHO-K1/CD80 cells were plated 15 h before adding Jurkat/IL-2-Luc Promoter cells, then Jurkat/IL-2-Luc Promoter cells were stimulated with a serial of concentrations of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) for 5 h. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway.

    Figure 3. Jurkat/IL-2-Luc Promoter cells were co-stimulated with a serial of concentrations of Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) and 1 μg/mL of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) for 5 h. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway.

  • 原代T細(xì)胞激活鑒定和細(xì)胞因子分泌檢測(cè)
    

    Figure 4. Primary T cells were stimulated with 5 μg/mL of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) (left), competing anti-Human CD3 antibody (middle), negative control (NC, right) as well as anti-Human CD28 antibody (all panels) for 72 h, respectively. CD25/CD69 expression was detected by flow cytometry to characterize cell activation.

    

    Figure 5. Primary T cell clumping was observed by a microscope after T cell activation (72 h) (right) using Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) and Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213). The inactivated T cells were presented on the left image.

    

    Figure 6. Interferon γ (IFN-γ) secretion by activated primary T cells using Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) and anti-Human CD28 antibody. Data showed that GenScript anti-Human CD3 antibody outperformed competing product.

    Figure 7. Interferon γ (IFN-γ) secretion by activated primary T cells using Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) and anti-Human CD3 antibody. Data showed that GenScript anti-Human CD28 antibody outperformed competing product.

• 抗人CD4和CD8抗體用于PBMC染色鑒定T細(xì)胞亞群

  抗CD抗體特異性識(shí)別細(xì)胞上表達(dá)的CD分子標(biāo)志物，可用于進(jìn)行細(xì)胞分群或功能鑒定。例如，CD4和CD8是PBMC染色中識(shí)別CD4+輔助T細(xì)胞和CD8+細(xì)胞毒性T細(xì)胞的常用標(biāo)志物。

  

  Figure 8. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-Human CD4 Antibody (F001), mAb, Mouse (Cat. No. A02211) (left), competing anti-human CD4 antibody (middle), mouse IgG1 negative control (NC, right) as well as with anti-Human CD3 [BV510] antibody (all panels). Flow cytometry was performed for further analysis. Cell debris and dead cells were excluded from the analysis based on scatter signals and 7-AAD.

  

  Figure 9. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-Human CD8 Antibody (F002), mAb, Mouse (Cat. No. A02122) (left), competing anti-Human CD8 antibody (middle), mouse IgG1 negative control (right) as well as with anti-Human CD3 [BV510] antibody (all panels). Flow cytometry was performed for further analysis. Cell debris and dead cells were excluded from the analysis based on scatter signals and 7-AAD.

產(chǎn)品性能

• 高批間一致性
  

  Figure 10. Lot-to-lot consistency was tested using four batches of Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) on Jurkat/IL-2-Luc Promoter cells. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway. Data showed that GenScript Anti-Human CD3 Antibody (OKT3), mAb, Mouse (Cat. No. A02199) has a high lot-to-lot consistency.

  Figure 11. Lot-to-lot consistency was tested using four batches of Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) on Jurkat/IL-2-Luc Promoter cells. Receptor-mediated signaling induced luminescence via activation of the IL-2 pathway. Data showed that GenScript Anti-Human CD28 Antibody (F105), mAb, Mouse (Cat. No. A02213) has a high lot-to-lot consistency.

• 高穩(wěn)定性
  

  Figure 12. Stability of GenScript GMP Anti-Human CD8 Antibody (F002), mAb, Mouse (Cat. No. GMPA02212) was tested. The data of long-term stability, accelerated stability, and freeze-thaw cycle stability indicated that this GMP antibody is very stable under various storage conditions.